{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:34Z","timestamp":1792601074902,"version":"4.5.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>IMPORTANCE:<\/jats:title>\n            <jats:p>Patients admitted to the ICU often experience gastrointestinal complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become increasingly prevalent in the treatment of type 2 diabetes mellitus and obesity, and there is evidence that their use may be associated with an increased risk of clinically significant gastrointestinal events. However, their impact on critically ill patients admitted to the medical ICU is unknown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>This study examined whether pre-ICU use of GLP-1RAs was associated with increased incidence of gastrointestinal complications and hospitalization outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN, SETTING AND PARTICIPANTS:<\/jats:title>\n            <jats:p>Multicenter, retrospective cohort study of critically ill patients admitted to academic and community hospitals of Mayo Clinic Health System from January 1, 2018, to December 31, 2023. Patients who were admitted to surgical ICUs and those who were exposed to GLP-1RA medications before but did not have an active prescription within 30 days of admission were excluded. Patients exposed to GLP-1RA were matched with those nonexposed in a 1:1 fashion based on demographic factors, factors affecting gastrointestinal motility, overall illness burden, and clinical acuity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n            <jats:p>Outcomes of interest were the development of gastrointestinal dysfunction, ICU- and hospital-free days, and mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>A total of 31,327 patients with diabetes or obesity were identified of whom these, 631 were exposed to GLP-1RA before admission. In the matched cohort of 1262 patients, baseline variables were evenly distributed between the two groups. There were no significant differences in the odds of developing nausea\/vomiting, constipation, ileus, obstruction, impaction, or aspiration pneumonia between the GLP-1RA exposed and unexposed groups. Similarly, ICU and hospital mortality rates were comparable across the two groups. However, GLP-1RA exposed patients had significantly more hospital-free days compared with unexposed patients (estimate, 1.19; 95% CI, 0.38\u20132.0; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.004).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS AND RELEVANCE:<\/jats:title>\n            <jats:p>GLP-1RA exposure was not associated with increased odds of clinically significant gastrointestinal complications in nonsurgical critically ill patients. Increased hospital-free days observed among GLP-1RA exposed patients requires further study.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000001263","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T15:00:30Z","timestamp":1747234830000},"page":"e1263","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Glucagon-Like Peptide-1 Receptor Agonist Exposure on Gastrointestinal Outcomes Among ICU Patients: A Multicenter Matched Cohort Study"],"prefix":"10.1097","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0750-4781","authenticated-orcid":false,"given":"Cameron G.","family":"Gmehlin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Nemet","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshan M.","family":"Rizwan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumera","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ognjen","family":"Gajic","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Tekin","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"R1-20250514","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1399-6576.2008.01860.x","article-title":"Gastrointestinal symptoms in intensive care patients.","volume":"53","author":"Reintam","year":"2009","journal-title":"Acta Anaesthesiol Scand"},{"key":"R2-20250514","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1378\/chest.119.4.1222","article-title":"GI complications in patients receiving mechanical ventilation.","volume":"119","author":"Mutlu","year":"2001","journal-title":"Chest"},{"key":"R3-20250514","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00134-006-0452-7","article-title":"Intestinal motility disturbances in intensive care patients pathogenesis and clinical impact.","volume":"33","author":"Fruhwald","year":"2007","journal-title":"Intensive Care Med"},{"key":"R4-20250514","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ccc.2015.11.003","article-title":"Gut Motility Issues in Critical Illness.","volume":"32","author":"Taylor","year":"2016","journal-title":"Crit Care Clin"},{"key":"R5-20250514","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s13054-021-03793-1","article-title":"The effect of opioids on gastrointestinal function in the ICU.","volume":"25","author":"Yan","year":"2021","journal-title":"Crit Care"},{"key":"R6-20250514","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0884533609357568","article-title":"Altered GI motility in critically Ill patients: current understanding of pathophysiology, clinical impact, and diagnostic approach.","volume":"25","author":"Ukleja","year":"2010","journal-title":"Nutr Clin Pract"},{"key":"R7-20250514","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40560-019-0372-6","article-title":"Gut integrity in critical illness.","volume":"7","author":"Otani","year":"2019","journal-title":"J Intensive Care"},{"key":"R8-20250514","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1304623","article-title":"Nutrition in the acute phase of critical illness.","volume":"370","author":"Casaer","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20250514","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40560-016-0156-1","article-title":"Risk factors for late defecation and its association with the outcomes of critically ill patients: a retrospective observational study.","volume":"4","author":"Fukuda","year":"2016","journal-title":"J Intensive Care"},{"key":"R10-20250514","first-page":"284","article-title":"Effect of constipation on outcomes in mechanically ventilated patients.","volume":"35","author":"Ali","year":"2022","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"R11-20250514","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.7326\/M24-0019","article-title":"Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis.","volume":"177","author":"Yeo","year":"2024","journal-title":"Ann Intern Med"},{"key":"R12-20250514","first-page":"8","article-title":"Poll: Roughly 12% of US adults have used a GLP-1 drug, even if unaffordable.","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"R13-20250514","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and dual agonists.","year":"2023"},{"key":"R14-20250514","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bph.15611","article-title":"Actions of glucagon-like peptide-1 receptor ligands in the gut.","volume":"179","author":"Holst","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R15-20250514","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions.","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R16-20250514","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ALN.0000000000004752","article-title":"Trust the gold standard: all glucagon-like peptide-1 receptor agonists can delay gastric emptying.","volume":"140","author":"Weber","year":"2024","journal-title":"Anesthesiology"},{"key":"R17-20250514","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","article-title":"Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA Adverse Event Reporting System Database.","volume":"42","author":"Wu","year":"2022","journal-title":"Clin Drug Investig"},{"key":"R18-20250514","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/ph17020199","article-title":"Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the National Institutes of Health All of US Cohort.","volume":"17","author":"Aldhaleei","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"R19-20250514","doi-asserted-by":"crossref","DOI":"10.1177\/20420986231181334","article-title":"Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.","volume":"14","author":"Stottlemyer","year":"2023","journal-title":"Ther Adv Drug Saf"},{"key":"R20-20250514","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R21-20250514","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cpt.2430","article-title":"Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes.","volume":"111","author":"Faillie","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R22-20250514","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss.","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"R23-20250514","first-page":"e26916","article-title":"Suspected gastroparesis with concurrent gastroesophageal reflux disease induced by low-dose liraglutide.","volume":"14","author":"Ishihara","year":"2022","journal-title":"Cureus"},{"key":"R24-20250514","doi-asserted-by":"crossref","first-page":"e01712","DOI":"10.1213\/XAA.0000000000001712","article-title":"Particulate gastric contents in patients prescribed glucagon-like peptide 1 receptor agonists after appropriate perioperative fasting: a report of 2 cases.","volume":"17","author":"Wilson","year":"2023","journal-title":"A A Pract"},{"key":"R25-20250514","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12630-023-02521-3","article-title":"Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report.","volume":"70","author":"Gulak","year":"2023","journal-title":"Can J Anaesth"},{"key":"R26-20250514","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2024.10.003","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.","author":"Kindel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R27-20250514","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/ofid\/ofab466.821","article-title":"623. Exploring \u2018Slicer Dicer\u2019, an extraction tool in EPIC, for clinical and epidemiological analysis.","volume":"8","author":"Saini","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R28-20250514","first-page":"S5","article-title":"Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013.","volume":"22","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"R29-20250514","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R30-20250514","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality.","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"R31-20250514","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/00003246-200208000-00016","article-title":"Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome.","volume":"30","author":"Schoenfeld","year":"2002","journal-title":"Crit Care Med"},{"key":"R32-20250514","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/cc9039","article-title":"Bench-to-bedside review: the gut as an endocrine organ in the critically ill.","volume":"14","author":"Deane","year":"2010","journal-title":"Crit Care"},{"key":"R33-20250514","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.2024.5003","article-title":"Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications.","volume":"331","author":"Dixit","year":"2024","journal-title":"JAMA"},{"key":"R34-20250514","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1111\/dom.15636","article-title":"Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.","volume":"26","author":"Klonoff","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"R35-20250514","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.cgh.2023.11.024","article-title":"Low incidence of pulmonary aspiration during upper endoscopy in patients prescribed a glucagon-like peptide 1 receptor agonist.","volume":"22","author":"Anazco","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R36-20250514","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cgh.2024.07.021","article-title":"Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis.","volume":"23","author":"Facciorusso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R37-20250514","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s13181-024-00999-x","article-title":"Glucagon-like peptide-1 receptor agonist cases reported to United States Poison Centers, 2017-2022.","volume":"20","author":"Gaw","year":"2024","journal-title":"J Med Toxicol"},{"key":"R38-20250514","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ajg.2016.28","article-title":"ACG clinical guideline: nutrition therapy in the adult hospitalized patient.","volume":"111","author":"McClave","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R39-20250514","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jpen.2267","article-title":"Guidelines for the provision of nutrition support therapy in the adult critically ill patient: the American Society for Parenteral and Enteral Nutrition.","volume":"46","author":"Compher","year":"2022","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"R40-20250514","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"R41-20250514","doi-asserted-by":"crossref","DOI":"10.1016\/j.artd.2024.101506","article-title":"Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total hip arthroplasty in patients who have type 2 diabetes.","author":"Heo","year":"2024","journal-title":"J Arthroplasty"},{"key":"R42-20250514","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2337\/cd22-0027","article-title":"Glucagon-like peptide 1 receptor agonists have the potential to revolutionize the attainment of target A1C levels in type 2 diabetes-so why is their uptake so low?","volume":"41","author":"King","year":"2023","journal-title":"Clin Diabetes"},{"key":"R43-20250514","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R44-20250514","doi-asserted-by":"crossref","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"R45-20250514","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity.","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"R46-20250514","doi-asserted-by":"crossref","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US.","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"key":"R47-20250514","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00134-016-4216-8","article-title":"Pre-morbid glycemic control modifies the interaction between acute hypoglycemia and mortality.","volume":"42","author":"Egi","year":"2016","journal-title":"Intensive Care Med"},{"key":"R48-20250514","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1097\/CCM.0000000000004599","article-title":"The interaction of acute and chronic glycemia on the relationship of hyperglycemia, hypoglycemia, and glucose variability to mortality in the critically ill.","volume":"48","author":"Krinsley","year":"2020","journal-title":"Crit Care Med"},{"key":"R49-20250514","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12913-015-0949-2","article-title":"Impact of socio-economic status on hospital length of stay following injury: a multicenter cohort study.","volume":"15","author":"Moore","year":"2015","journal-title":"BMC Health Serv Res"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T15:00:38Z","timestamp":1747234838000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000001263","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}